Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001442266 | SCV001645214 | likely benign | Cohen syndrome | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001442266 | SCV003820437 | uncertain significance | Cohen syndrome | 2021-06-18 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003399230 | SCV004105312 | uncertain significance | VPS13B-related disorder | 2023-02-28 | criteria provided, single submitter | clinical testing | The VPS13B c.9035C>G variant is predicted to result in the amino acid substitution p.Thr3012Ser. This variant has been reported as a variant of uncertain significance in an individual with autism (Mercati et al. 2017. PubMed ID: 27166760). This variant is reported in 0.10% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/8-100833562-C-G) and has conflicting interpretations of pathogenicity ranging from benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/1114508/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004038403 | SCV004976275 | uncertain significance | Inborn genetic diseases | 2024-01-24 | criteria provided, single submitter | clinical testing | The c.9110C>G (p.T3037S) alteration is located in exon 50 (coding exon 49) of the VPS13B gene. This alteration results from a C to G substitution at nucleotide position 9110, causing the threonine (T) at amino acid position 3037 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001442266 | SCV002082698 | benign | Cohen syndrome | 2021-02-22 | no assertion criteria provided | clinical testing |